Attana biosensors provides a reliable, fast and versatile label-free method to study molecular interactions.
Accelerate to discover
Related topics
InAlyzer to evaluate G6PD activity in relation with frailty
Mar 28, 2023
InAlyzer is body densitometry instrument for lab animals, equipped with 2 X-Ray sources and able to provide valuable...
Flash news - did you know, that you can use Singulator S100 also for plant research?
Feb 10, 2023
In this short TechNote you can find how Singulator can help the data quality in Single cell sequencing - now even in...
Extensive assessment of Cytokine production on the NovoCyte Advanteon flow cytometer
Jan 13, 2023
Cytokines are small molecules essential for immune cell response to activation by pathogens, autoimmunity, or...
Microfluidic cell sorter sample preparation for genomic assays
Dec 16, 2022
Single-cell RNA-Sequencing has led to many novel discoveries such as the detection of rare cell populations, microbial...
Demonstrate the value of RareCyte Orion system via web-based Minerva viewer
Nov 25, 2022
The HTA CRC Atlas X dataset contains images and other data being used for construction of an atlas of human colorectal...
All inside your incubator: xCELLigence eSight
Nov 3, 2022
Multiplex Live cell imaging and real-time biosensor measurement with xCELLigence eSight
RareCyte Orion system advances Multi-modal digital pathology for colorectal cancer diagnosis
Oct 19, 2022
Precision medicine is critically dependent on better methods for diagnosing and staging disease and predicting drug...
Jun 14, 2016
The team of Professor Dr. Roland Kontermann at the Institute of Cell Biology and Immunology, University of Stuttgart, Germany has recently published an article in PLOS ONE titled A Fab-Selective Immunoglobulin-Binding Domain from Streptococcal Protein G with Improved Half-Life Extension Properties.
Professor Kontermann's group is working on the development of novel strategies for tumor therapy. The strategies are based on the use of specific ligands to target potent cytotoxic effector mechanism to the tumor. Their focus is on three effector arms: 1) bispecific antibodies for the retargeting of effector cells of the immune system (immunotherapy), 2) targeted carrier systems (liposomes, polymers) for drug delivery (chemotherapy), and 3) targeted cytotoxic fusion proteins (biotherapy). Main targets are molecules associated with the tumor vasculature (vascular targeting), since these structures are easily accessible for circulating agents and all solid tumors are dependent on vascularisation.
In this publication the group employed their Attana A200 system for affinity determination.
Related technologies: Label-free protein analysis
Brand profile
Attana biosensors provides a reliable, fast and versatile label-free method to study molecular interactions.
More info at:
www.attana.com/